

Office of Economic Development

Joseph C. King City Manager City of Danville Jeremy Stratton Director Office of Economic Development

For Immediate Release

Contact:Jeremy StrattonOffice:434.793.1753Mobile:434.489.6135Email:jstratton@discoverdanville.com

Engineered Biopharmaceuticals Carl Sahi Mobile: 860-803-7437

crsahi@engbiopharm.com

October 12, 2011

~Engineered BioPharmaceuticals is leveraging a local creative workforce and American ingenuity to improve the efficiency of healthcare delivery.~

(Danville, VA) The Office of Economic Development of the City of Danville is pleased to formally announce the location of Engineered BioPharmaceuticals Inc. in the Dan River Business Development Center. Engineered BioPharmaceuticals is a state of the art, pharmaceutical processing company embarking on a novel method of converting solutions of vaccines and therapeutic drugs into dry powder that will offer significant cost savings to the public.

Engineered BioPharmaceuticals has received a \$3 million research grant from the National Institute of Standards and Technology as well as \$3 million from the Virginia Tobacco Commission in order to pursue further research and development and expand the company. Currently working out of the Dan River Business Development Center, Engineered BioPharmaceuticals plans to expand in about three years to a larger manufacturing site in Danville's Cyber Park and create about 100 jobs for highly skilled professionals and technicians.

The company's President, Carl Sahi, said today, "We are impressed with the community's support and the capable and creative talent base we have found so far in the region. It is exciting to know we can draw from such a resource pool to build our future growth and successes upon." Today, the company has eleven employees working at its site in the Business Development Center.

The cost of healthcare is causing great concern both as a national policy issue and an individual financial burden. Many of the newest and most effective drugs have limited storage stability and often require refrigerated storage. Protein based drugs, which are becoming more and more prevalent in the arsenal of medications, usually cannot be taken orally because they are destroyed by the acidic conditions in the stomach and, therefore, must be injected. These newer drug therapies and preventive vaccines are being more widely prescribed, but patients are having difficulty following their doctors' orders because of undesirable and/or inconvenient administration. Advancing technology is not in step with the needs of the patient and is thus creating higher and higher costs that we must find ways to control.

Amidst the intense national debate over controlling healthcare costs from the top down, medical therapies that win the support and active participation of patients are the ultimate drivers to control costs and bring efficiency to our healthcare system from the bottom up. Lackluster patient compliance is estimated to cost the healthcare system upwards of \$300 billion per year. To support better patient compliance, pharmaceutical delivery systems need to be convenient for the user/patient. Particularly for chronic treatments, patients must have the ability to fit pharmaceutical therapeutic treatments into their busy lifestyles and personal schedules.

Engineered BioPharmaceuticals, a developer of new drug delivery technologies, is feverishly working in Danville to enhance the future of drug delivery. The company is developing finely engineered, dry powder pharmaceuticals that can extend a product's shelf-life and make the product more stable at room temperature. These engineered dry powders have faster dissolution after ingestion and allow liquid injectables to be compliantly self-administered through alternate time-of-use, self-reconstituting micro injections or dry powder intranasal and inhalation methods. Adding these user friendly features broadens the range of individuals who can be treated with a single therapy. Jack Polidoro, the company's Vice President of R&D said, "We are fortunate to be working with forward thinking pharmaceutical clients who understand the patient is at the center of performance based, personalized medicine." Engineered dry powder delivery platforms also make critical vaccines and therapeutics readily available for mass distribution and administration in time of national need.